Evogene Ltd.
EVGN
$0.76
-$0.02-2.05%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.31M | -4.46M | 427.00K | -7.63M | -3.98M |
| Total Depreciation and Amortization | 263.00K | 290.00K | 441.00K | 209.00K | 661.00K |
| Total Amortization of Deferred Charges | 334.00K | 330.00K | 334.00K | 137.00K | -- |
| Total Other Non-Cash Items | 2.26M | 555.00K | -5.37M | 2.16M | 530.00K |
| Change in Net Operating Assets | -233.00K | 986.00K | -395.00K | -447.00K | -1.52M |
| Cash from Operations | -2.69M | -2.30M | -4.56M | -5.58M | -4.32M |
| Capital Expenditure | -6.00K | -2.00K | -322.00K | -137.00K | -216.00K |
| Sale of Property, Plant, and Equipment | 47.00K | -- | 0.00 | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.22M | -987.00K | 9.08M | 2.15M | 3.86M |
| Cash from Investing | 10.26M | -989.00K | 8.76M | 2.02M | 3.64M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -133.00K | -137.00K | -310.00K | -106.00K | -211.00K |
| Issuance of Common Stock | 0.00 | 4.28M | 0.00 | 5.54M | 8.07M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -123.00K | 3.00K | 104.00K | -50.00K | -58.00K |
| Cash from Financing | -256.00K | 4.15M | -206.00K | 5.38M | 7.80M |
| Foreign Exchange rate Adjustments | 9.00K | 45.00K | -7.00K | 11.00K | -28.00K |
| Miscellaneous Cash Flow Adjustments | -- | -70.00K | -- | -- | -- |
| Net Change in Cash | 7.33M | 834.00K | 3.98M | 1.83M | 7.10M |